PROGNOSTIC INDICATORS IN HORMONE REFRACTORY PROSTATE CANCER
- 1 May 1999
- journal article
- review article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 26 (2), 303-310
- https://doi.org/10.1016/s0094-0143(05)70070-7
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976—1996Urology, 1998
- Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancerZeitschrift für Krebsforschung und Klinische Onkologie, 1996
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study GroupPublished by American Medical Association (AMA) ,1991
- Multivariate Analysis of Prognostic Factors in Patients with Advanced Prostatic Cancer: Results from 2 European Organization for Research on Treatment of Cancer TrialsJournal of Urology, 1989
- A comparative clinical trial of adriamycin and 5‐fluorouracil in advanced prostatic cancer: Prognostic factors and responseThe Prostate, 1983
- Systemic Treatment of Advanced Prostatic Cancer: Development of a New System for Defining ResponseJournal of Urology, 1981
- Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significanceCancer, 1979
- Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostateCancer, 1979
- Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomiesCancer, 1972